A recent study has shown that targeted PET imaging using the amino acid tracer floretyrosine F 18 can effectively differentiate between recurrent gliomas and radiation necrosis in patients. The clinical trial involved 127 patients and demonstrated a positive percent agreement of 70% to 83% for detecting true recurrence across multiple readers. Among pediatric patients, the agreement reached 83%. The study reported that unlike conventional imaging techniques, this method provides improved tumor-to-background contrast, enhancing diagnostic accuracy and potentially reducing unnecessary invasive procedures. The overall safety profile was favorable, with headache being the most common adverse reaction. This advancement in PET imaging could significantly improve post-treatment surveillance in neuro-oncology, facilitating timely interventions for patients.
Fri, 18 Sep 2026 09:02:11 GMT | EMJ